Analyst Derek Archila from Wells Fargo maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) and keeping the price ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

A list of downloadable documents created during development.

Title:Clinical Activity of NX-5948 in CLL & NHL: A First-in-Class BTK Degrader Presenting author: Paula G. O’Connor, M.D., ...

In a report released today, Peter Lawson from Barclays assigned a Buy rating to Nurix Therapeutics (NRIX – Research Report), with a price ...

Schrödinger's stock has fallen 64% since January 2023, driven by missed revenue and EPS targets. Read why I maintain my hold ...

“These posters, as well as an additional focus on our assay development ... the combination potential for MALT1 and BTK inhibitors in models of B-cell malignancies, PD biomarkers related ...

BeiGene's BTK inhibitor ... another B-cell NHL, around a year after it was cleared for the new use in the US. If approved, the drug will be the first and only approved BTK inhibitor for MZL ...

Fenebrutinib is currently the only reversible, non-covalent inhibitor of BTK in late-stage development, which Roche maintains could translate into a cleaner side effect profile than other drugs in ...

The following is a summary of “Altered B-cell, plasma cell and antibody immune profiles in blood of systemic mastocytosis,” published in the October 2024 issue of Allergy and Immunology by Pérez- Pons ...

"I am delighted to welcome Anil to the Nurix board as we enter this important stage in the company's development and execute ...